John Paul Shen is a native of St. Louis, MO, and remains a dedicated supporter of the St. Louis Cardinals. He studied chemistry at the Massachusetts Institute of Technology, graduating in 2002 with selection to the Phi Beta Kappa honor society. Dr. Shen completed his medical education at Washington University in St. Louis, taking one year off to participate in a Howard Hughes Medical Institute research fellowship at the Broad Institute of Harvard and MIT under the direction of Drs. Stuart Schreiber and James Bradner. Currently a second-year fellow in hematology and oncology, Dr. Shen is now working in the laboratory of Dr. Trey Ideker. His research interests include cancer biology with a focus on identifying new chemotherapeutic targets and the development of novel chemotherapeutic compounds.
Bradner JE, Mak R, Tanguturi SK, Mazitschek R, Haggarty SJ, Ross K, Chang CY, Bosco J, West N, Morse E, Lin K, Shen JP, Kwiatkowski NP, Gheldof N, Dekker J, DeAngelo DJ, Carr SA, Schreiber SL, Golub TR, Ebert BL. Chemical genetic strategy identifies HDAC1 ad HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci. July 2010; 107 (28) 12617-22. PMID: 20616024
Bradner JE, McPherson OM, Mazitschek R, Barnes-Seeman D, Shen JP, Dhaliwal J, Stevenson KE, Duffner JL, Park SB, Neuberg DS, Nghiem P, Schreiber SL, Koehler AN. A robust small-molecule microarray platform for screening cell lysates. Chem Biol. May 2006; 5 (5) 493-504. PMID: 16720270
Shen JP, Divakaran S, Ponduro S, Vogl DT, Amaravadi RK, Bradner JE. The rational for combined proteasome and autophagy inhibition in multiple myeloma established using novel translational platforms. Blood (ASH Annual Meeting Abstracts). Nov 2008; 112: 2755
Shen JP, Divakaran S, Kuai LT, Wang X, Ong SE, Amaravadi R, Wood J, Carr S, Haggarty S, Bradner JE. Autophagy as a Target Pathway in Multiple Myeloma: a Forward Chemical Genetic Approach. Blood (ASH Annual Meeting Abstracts). Nov 2007; 110 (11) 2510.
Shen JP, Greenberg EF, Hideshima T, Anderson KC, Schreiber SL, Bradner JE. Targeting the Protein Degradation Pathway in Multiple Myeloma with Synergistic, Selective Small Molecules. Blood (ASH Annual Meeting Abstracts). Nov 2005; 106 (11) 2471.